Ranked #1,903 of 8,699 institutional investors
ARCH Venture Management, LLC
Chicago, IL
$1.42B
US stock portfolio at live prices · today +$1.1M (+0.08%)
Market closed. Prices as of Nov 20, 8:41 AM ET
- Value at quarter end (Q3 2026)
- $1.61B
- Change from Q2 2026
- +$513.1M (+46.63%)
- Positions
- 17 · 6 new, 1 sold out
- Filed
- Nov 16, 2026
Holdings
Q3 2026 13F, live pricesKARD 13.3%PBLS 12.5%MAZE 9.43%SRRK 8.34%SPTX 8.14%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| KARD Kardigan, Inc. | 15,042,036 | $188M | 13.3% | New |
| PBLS Parabilis Medicines, Inc. | 6,412,780 | $177M | 12.5% | Unchanged |
| MAZE Maze Therapeutics, Inc. | 4,120,053 | $134M | 9.43% | Unchanged |
| SRRK Scholar Rock Holding Corporation | 2,345,711 | $118M | 8.34% | New |
| SPTX Seaport Therapeutics, Inc. | 6,294,951 | $115M | 8.14% | Unchanged |
| VIR Vir Biotechnology, Inc. | 12,694,163 | $113M | 7.95% | Unchanged |
| ERAS Erasca, Inc. | 7,091,557 | $101M | 7.12% | Unchanged |
| BEAM Beam Therapeutics Inc. | 4,540,132 | $95.1M | 6.71% | Unchanged |
| RAPP Rapport Therapeutics, Inc. | 3,728,738 | $88.0M | 6.21% | Unchanged |
| SANA Sana Biotechnology, Inc. | 45,860,681 | $79.8M | 5.63% | New |
| PRME Prime Medicine, Inc. | 18,486,894 | $71.0M | 5.01% | New |
| MASS 908 Devices Inc. | 5,725,045 | $53.6M | 3.79% | New |
| LYEL Lyell Immunopharma, Inc. | 3,247,162 | $44.1M | 3.11% | Unchanged |
| GENB Generate Biomedicines, Inc. | 1,944,426 | $20.2M | 1.42% | Unchanged |
| NMRA Neumora Therapeutics, Inc. | 33,847,838 | $11.7M | 0.83% | New |
| BOLD Boundless Bio, Inc. | 2,694,095 | $6.4M | 0.45% | Unchanged |
| GOSS Gossamer Bio, Inc. | 100,698 | $1.1M | <0.1% | Unchanged |
Sold out in Q3 2026
| Stock | Shares held at Q2 2026 | Worth today |
|---|---|---|
| TXG 10x Genomics, Inc. | 217,834 | $12.5M |